Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Rapid Acting Intramuscular Olanzapine
Drug: Isotonic sodium chloride solution

First Posted Date: 2008-03-21

Last Posted Date: 2009-09-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 34

Registration Number: NCT00640510

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamagata, Japan

Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Atomoxetine

First Posted Date: 2008-03-14

Last Posted Date: 2010-11-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 45

Registration Number: NCT00636818

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

Safety Study of Atomoxetine and Cerebrovascular Outcomes

Completed

Conditions: Cerebrovascular Accident
Transient Ischemic Attack
ADHD

Interventions: Drug: Stimulants
Other: No intervention (general population)
Drug: atomoxetine

First Posted Date: 2008-03-13

Last Posted Date: 2009-09-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72000

Registration Number: NCT00634439

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Indianapolis, Indiana, United States

A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Placebo
Drug: LY2189265

First Posted Date: 2008-03-07

Last Posted Date: 2014-12-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 262

Registration Number: NCT00630825

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toa Baja, Puerto Rico

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Biological: Ramucirumab (IMC-1121B)

First Posted Date: 2008-02-29

Last Posted Date: 2014-10-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 42

Registration Number: NCT00627042

Locations: 🇺🇸
ImClone Investigational Site, Philadelphia, Pennsylvania, United States

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer
Locally Advanced Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Bevacizumab

First Posted Date: 2008-02-25

Last Posted Date: 2012-01-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 52

Registration Number: NCT00623233

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newport News, Virginia, United States

A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: LY2181308 sodium
Drug: cytarabine
Drug: idarubicin

First Posted Date: 2008-02-21

Last Posted Date: 2019-09-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT00620321

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States

Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

Phase 3

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: Olanzapine

First Posted Date: 2008-02-20

Last Posted Date: 2011-07-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 101

Registration Number: NCT00618748

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: IMC-A12 (cixutumumab)
Biological: cetuximab (Erbitux ®)

First Posted Date: 2008-02-18

Last Posted Date: 2018-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 97

Registration Number: NCT00617734

Locations: 🇺🇸
ImClone Investigational Site, Charlottesville, Virginia, United States

Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Placebo
Drug: Enzastaurin
Drug: Leucovorin (LV)
Drug: 5-fluorouracil (5-FU)
Drug: Bevacizumab (Bev)

First Posted Date: 2008-02-11

Last Posted Date: 2020-07-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 117

Registration Number: NCT00612586

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy